Hematopoietic stem cell (HSC) gene therapy is a demonstrated effective treatment for X-linked severe combined immunodeficiency (SCID-X1), but B-cell reconstitution and function has been deficient in many of the gene therapy treated patients. Cytoreductive preconditioning is known to improve HSC engraftment, but in general it is not considered for SCID-X1 since the poor health of most of these patients at diagnosis and the risk of toxicity preclude the conditioning used in standard bone marrow stem cell transplantation. We hypothesized that mobilization of HSC by granulocyte colony-stimulating factor (G-CSF) should create temporary space in bone marrow niches to improve engraftment and thereby B-cell reconstitution. In the present pilot study supplementing our earlier preclinical evaluation (Huston et al., 2011), Il2rg−/− mice pretreated with G-CSF were transplanted with wild-type lineage negative (Lin−) cells or Il2rg−/− Lin− cells transduced with therapeutic IL2RG lentiviral vectors. Mice were monitored for reconstitution of lymphocyte populations, level of donor cell chimerism, and antibody responses as compared to 2 Gy total body irradiation (TBI), previously found effective in promoting B-cell reconstitution. The results demonstrate that G-CSF promotes B-cell reconstitution similar to low-dose TBI and provides proof of principle for an alternative approach to improve efficacy of gene therapy in SCID patients without adverse effects associated with cytoreductive conditioning.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., WebbI.J., BleulC., et al. (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med., 185, 111–120.
2.
AiutiA., CassaniB., AndolfiG., et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest., 117, 2233–2240.
3.
AiutiA., CattaneoF., GalimbertiS., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360, 447–458.
4.
AiutiA., BiascoL., ScaramuzzaS., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.
5.
AntoineC., MullerS., CantA., et al. (2003). Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet, 361, 553–560.
6.
ArmitageJ.O. (1994). Bone marrow transplantation. N. Engl. J. Med., 330, 827–838.
7.
BareseC., PechN., DirscherlS., et al. (2007). Granulocyte colony-stimulating factor prior to nonmyeloablative irradiation decreases murine host hematopoietic stem cell function and increases engraftment of donor marrow cells. Stem Cells, 25, 1578–1585.
8.
BensingerW.I., BucknerC.D., RowleyS., et al. (1996). Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant. 17Suppl 2, S19–S21.
BroxmeyerH.E., OrschellC.M., ClappD.W., et al. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med., 201, 1307–1318.
11.
BuckleyR.H. (2004). Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol., 22, 625–655.
12.
BushmanF.D. (2007). Retroviral integration and human gene therapy. J. Clin. Invest., 117, 2083–2086.
13.
CampbellT.B., HangocG., LiuY., et al. (2007). Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev., 16, 347–354.
14.
Cavazzana-CalvoM., LagresleC., Hacein-Bey-AbinaS., and FischerA. (2005). Gene therapy for severe combined immunodeficiency. Annu. Rev. Med., 56, 585–602.
15.
Cavazzana-CalvoM., FischerA., Hacein-Bey-AbinaS., and AiutiA. (2012). Gene therapy for primary immunodeficiencies: part 1. Curr. Opin. Immunol., 24, 580–584.
16.
ChenJ., LarochelleA., FrickerS., et al. (2006). Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood, 107, 3764–3771.
17.
CynshiO., SatohK., ShimonakaY., et al. (1991). Reduced response to granulocyte colony-stimulating factor in W/Wv and Sl/Sld mice. Leukemia, 5, 75–77.
18.
DeichmannA., BrugmanH.M., BartholomaeC.C., et al. (2011). Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol. Ther., 19, 2031–2039.
19.
DiPersioJ.F., StadtmauerE.A., NademaneeA., et al. (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 5720–5726.
20.
ElfenbeinG.J., and SacksteinR. (2004). Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp. Hematol., 32, 327–339.
21.
EspeliM., ManciniS.J., BretonC., et al. (2009). Impaired B-cell development at the pre-BII-cell stage in galectin-1-deficient mice due to inefficient pre-BII/stromal cell interactions. Blood, 113, 5878–5886.
22.
FischerA. (1999). Thirty years of bone marrow transplantation for severe combined immunodeficiency. N. Engl. J. Med., 340, 559–561.
23.
FischerA., and Cavazzana-CalvoM. (2008). Gene therapy of inherited diseases. Lancet, 371, 2044–2047.
24.
FollenziA., and NaldiniL. (2002). HIV-based vectors. Preparation and use. Methods Mol. Med., 69, 259–274.
25.
GasparH.B., ParsleyK.L., HoweS., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 364, 2181–2187.
26.
GasparH.B., CoorayS., GilmourK.C., et al. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med., 3, 97ra79.
27.
GenneryA.R., SlatterM.A., GrandinL., et al. (2010). Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?. J. Allergy Clin. Immunol., 126, 602–610e1–e11.
28.
GiriN., KaushivaA., WuT., et al. (2001). The effects of SCF/G-CSF prestimulation on radiation sensitivity and engraftment in nonmyeloablated murine hosts. Exp. Hematol., 29, 779–785.
29.
GreenbaumA.M., and LinkD.C. (2011). Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia, 25, 211–217.
30.
Hacein-Bey-AbinaS., GarrigueA., WangG.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132–3142.
31.
Hacein-Bey-AbinaS., HauerJ., LimA., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363, 355–364.
32.
HaddadE., LeroyS., and BuckleyR.H. (2013). B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?. J. Allergy Clin. Immunol., 131, 994–1000.
33.
HendrixC.W., FlexnerC., MacFarlandR.T., et al. (2000). Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother., 44, 1667–1673.
34.
HoggattJ., SinghP., SampathJ., and PelusL.M. (2009). Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood, 113, 5444–5455.
35.
HoweS.J., MansourM.R., SchwarzwaelderK., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118, 3143–3150.
36.
HustonM.W., Van TilN.P., VisserT.P., et al. (2011). Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol. Ther., 19, 1867–1877.
37.
HustonM.W., BrugmanM.H., HorsmanS., et al. (2012). Comprehensive investigation of parameter choice in viral integration site analysis and its effects on the gene annotations produced. Hum. Gene Ther., 23, 1209–1219.
38.
KahnJ., BykT., Jansson-SjostrandL., et al. (2004). Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood, 103, 2942–2949.
39.
KnightS., ZhangF., Mueller-KullerU., et al. (2012). Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J. Virol., 86, 9088–9095.
40.
KolletO., DarA., ShivtielS., et al. (2006). Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med., 12, 657–664.
41.
KustikovaO., FehseB., ModlichU., et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308, 1171–1174.
MacFarlandR., HardM.L., ScarboroughR., et al. (2010). A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol. Blood Marrow Transplant., 16, 95–101.
44.
MaloneyD.G., LilesT.M., CzerwinskiD.K., et al. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457–2466.
45.
MardineyM.3rd, and MalechH.L. (1996). Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood, 87, 4049–4056.
46.
MeijneE.I., Van Der Winden-Van GroenewegenR.J., PloemacherR.E., et al. (1991). The effects of x-irradiation on hematopoietic stem cell compartments in the mouse. Exp. Hematol., 19, 617–623.
47.
MourcinF., BretonC., TellierJ., et al. (2011). Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood, 117, 6552–6561.
48.
MukherjeeS., and ThrasherA.J. (2013). Gene therapy for PIDs: progress, pitfalls and prospects. Gene, 525, 174–181.
49.
NoguchiM., YiH., RosenblattH.M., et al. (1993). Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell, 73, 147–157.
50.
PeledA., PetitI., KolletO., et al. (1999). Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science, 283, 845–848.
51.
PetitI., Szyper-KravitzM., NaglerA., et al. (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol., 3, 687–694.
52.
PujalJ.M., and GallardoD. (2008). PCR-based methodology for molecular microchimerism detection and quantification. Exp. Biol. Med. (Maywood), 233, 1161–1170.
53.
RochaV., WagnerJ.E.Jr., SobocinskiK.A., et al. (2000). Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med., 342, 1846–1854.
54.
SchmidtM., SchwarzwaelderK., BartholomaeC., et al. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods, 4, 1051–1057.
55.
ShierL.R., SchultzK.R., ImrenS., et al. (2004). Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol. Blood Marrow Transplant., 10, 624–634.
56.
SpiegelA., ShivtielS., KalinkovichA., et al. (2007). Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat. Immunol., 8, 1123–1131.
57.
StewartF.M., ZhongS., WuuJ., et al. (1998). Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood, 91, 3681–3687.
58.
TomitaY., SachsD.H., and SykesM. (1994). Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood, 83, 939–948.
59.
WagemakerG., VisserT.P., and Van BekkumD.W. (1986). Cure of murine thalassemia by bone marrow transplantation without eradication of endogenous stem cells. Transplantation, 42, 248–251.
60.
WeerkampF., BaertM.R., BrugmanM.H., et al. (2006). Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. Blood, 107, 3131–3137.
61.
WhettonA.D., and GrahamG.J. (1999). Homing and mobilization in the stem cell niche. Trends Cell Biol, 9, 233–238.
62.
WinklerI.G., and LevesqueJ.P. (2006). Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp. Hematol., 34, 996–1009.
63.
WinklerI.G., SimsA.N., PettitA.R., et al. (2010). Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 116, 4815–4828.
64.
WinklerI.G., PettitA.R., RaggattL.J., et al. (2012). Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia, 26, 1594–1601.
65.
WognumA.W., VisserT.P., PetersK., et al. (2000). Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells. Hum. Gene Ther., 11, 2129–2141.
66.
ZhangC.C., KabaM., GeG., et al. (2006). Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat. Med., 12, 240–245.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
